Is Arrowhead Pharmaceuticals, Inc. (0HI3.L) a Buy, Sell, or Hold?
LSE : 0HI3.L
Arrowhead Pharmaceuticals, Inc.
$85.88 USD
-$1.79 (-2.04%)
- Volume
- 573
- Average Volume
- 1.78K
- Market Capitalization
- $11.95B
- P/E Ratio
- -40.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $88.98
- Year Low
- $20.75
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.23
Company Overview
LSE
Christopher R. Anzalone
Biotechnology
Healthcare
0HI3.L
711
US
USD
Liquidity Metrics
2.24
6.23
6.23
0.64
0.00
Sales & Valuation
$829.45M
19.38
19.86
-237.01
-0.36
Profitability
-$0.0122
-$1.63M
-48.38%
-40.56%
-55.45%
-13.27%
P/E Metrics
-40.00
0.00
0.00
Analyst Price Target & Rating
1/5
22 Analysts
%
Financial Health Scores
4.05
3/9
$1.54B
$2.27B
$1.67B
-$187.38M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Bruce D. Given | Chief Medical Scientist |
| Christopher R. Anzalone | Chairman, Chief Executive Officer & President |
| James C. Hamilton | Chief Medical Officer and Head of R&D |
| Mark Davis | Founder and Founder & Director of Insert Therapeutics Inc & Calando |
| Mark Seefeld | Head of Toxicology & Vice President |
| Tao Pei | Chief Scientific Officer |
| Vincent Anzalone | Head of Investor Relations & Vice President |
| Daniel J. Apel | Chief Financial Officer |
| Patrick O'Brien | COO & Secretary |
| Howard Lovy | Director of Communications |
Poll Results
No votes yet today — be the first to share your view!
About Arrowhead Pharmaceuticals, Inc. (LSE:0HI3.L) Stock
Arrowhead Pharmaceuticals, Inc. is a U.S.-based company focused on developing innovative medicines for the treatment of challenging and difficult-to-treat diseases. The company's extensive development pipeline features several RNA interference (RNAi) therapeutic candidates. These include: ARO-AAT: Currently in Phase II clinical trials for liver diseases associated with alpha-1 antitrypsin deficiency. ARO-APOC3: Advancing through both Phase 2b and Phase 3 clinical studies for hypertriglyceridemia. ARO-ANG3: Undergoing Phase 2b clinical evaluation for dyslipidemia. ARO-HSD: Having successfully completed Phase 1/2 clinical trials for various liver diseases. ARO-ENaC2: In preclinical development for dyslipidemia linked to cystic fibrosis. ARO-C3: In Phase 1/2a clinical trials, designed to redu ... ce the production of complement component 3. ARO-DUX4: A preclinical candidate targeting facioscapulohumeral muscular dystrophy. ARO-XDH: In Phase 1 clinical trials for refractory gout. ARO-COV: A preclinical program focused on COVID-19. ARO-RAGE: In Phase 1/2a clinical trials for muco-obstructive or inflammatory pulmonary conditions. ARO-MMP7: Also in Phase 1/2a clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). Beyond its proprietary programs, Arrowhead is actively involved in the development of other significant therapeutics: JNJ-3989: A subcutaneously administered RNAi therapeutic aimed at chronic hepatitis B virus infection. Olpasiran: Designed to decrease the synthesis of apolipoprotein A. ARO-AMG1: Targeting genetically validated pathways for cardiovascular disease. Arrowhead Pharmaceuticals maintains strategic licensing and research collaborations. It partners with Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics JNJ-75220795, ARO-JNJ2, and ARO-JNJ3, all of which target liver-expressed pathways. Additionally, the company has a research and license agreement with Takeda Pharmaceuticals U.S.A., Inc. for an RNAi therapeutic candidate intended for liver disease. Established in 1989, Arrowhead Pharmaceuticals, Inc. operates from its corporate headquarters in Pasadena, California.
Frequently Asked Questions
-
What is the current Arrowhead Pharmaceuticals, Inc. (0HI3.L) stock price?
-
Arrowhead Pharmaceuticals, Inc.(LSE:0HI3.L) stock price is $85.88 in the last trading session. During the trading session, 0HI3.L stock reached the peak price of $88.98 while $20.75 was the lowest point it dropped to. The percentage change in 0HI3.L stock occurred in the recent session was --2.04% while the dollar amount for the price change in 0HI3.L stock was -$1.79.
-
0HI3.L's industry and sector of operation?
-
The LSE listed 0HI3.L is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of 0HI3.L?
-
Bruce D. Given | Chief Medical Scientist
Christopher R. Anzalone | Chairman, Chief Executive Officer & President
James C. Hamilton | Chief Medical Officer and Head of R&D
Mark Davis | Founder and Founder & Director of Insert Therapeutics Inc & Calando
Mark Seefeld | Head of Toxicology & Vice President -
How many employees does 0HI3.L have?
-
Number of 0HI3.L employees currently stands at 711. 0HI3.L operates from 177 East Colorado Boulevard, Pasadena, CA 91105, US.
-
Link for 0HI3.L official website?
-
Official Website of 0HI3.L is: https://arrowheadpharma.com
-
How do I contact 0HI3.L?
-
0HI3.L could be contacted at phone #626 304 3400 and can also be accessed through its website. 0HI3.L operates from 177 East Colorado Boulevard, Pasadena, CA 91105, US.
-
How many shares of 0HI3.L are traded daily?
-
The average number of 0HI3.L shares traded daily for last 3 months was 1.78K.
-
What is the market cap of 0HI3.L currently?
-
The market value of 0HI3.L currently stands at $11.95B with its latest stock price at $85.88